Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s IT Overhaul Stagnating Despite Massive Spending, GAO Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency has not been able to get rid of outdated IT systems despite spending more than $160 million to date on a program designed to do that among other goals.

You may also be interested in...



FDA Solves One IT Challenge, But More Tech Hurdles Await – And Congress Is Watching

Congressional scrutiny of FDA’s overall document management challenges unlikely to let up despite adverse event success story.

FDA Seeks New Chief Information Officer In Privacy And Security Overhaul

The CIO will help develop policy to protect sensitive information while balancing individual privacy and security. FDA restructured the organization with a chief health informatics officer – focused on research, development, scientific computing and big data – and the CIO for software development and deployment, infrastructure and customer service.

FDA Seeks New Chief Information Officer In Privacy And Security Overhaul

The CIO will help develop policy to protect sensitive information while balancing individual privacy and security. FDA restructured the organization with a chief health informatics officer – focused on research, development, scientific computing and big data – and the CIO for software development and deployment, infrastructure and customer service.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel